[go: up one dir, main page]

MX356965B - Composiciones y metodos para profilaxis y tratamiento de adicciones. - Google Patents

Composiciones y metodos para profilaxis y tratamiento de adicciones.

Info

Publication number
MX356965B
MX356965B MX2014002627A MX2014002627A MX356965B MX 356965 B MX356965 B MX 356965B MX 2014002627 A MX2014002627 A MX 2014002627A MX 2014002627 A MX2014002627 A MX 2014002627A MX 356965 B MX356965 B MX 356965B
Authority
MX
Mexico
Prior art keywords
treating
addictive
relapse
methods
addiction
Prior art date
Application number
MX2014002627A
Other languages
English (en)
Inventor
Ciccocioppo Roberto
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX356965B publication Critical patent/MX356965B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar o prevenir la adicción y el uso reincidente de agentes adictivos y para tratar o prevenir un comportamiento adictivo o compulsivo y la práctica reincidente de un comportamiento adictivo o compulsión, al administrar un agonista del receptor activado por proliferadores peroxisomales gamma (PPAR?), solo o en combinación con otro agente terapéutico, tal como, por ejemplo, un antagonista de receptores opiáceos o un antidepresivo. La presente invención también incluye composiciones farmacéuticas para tratar o prevenir la adicción o reincidencia que incluyen un agonista del PPAR? y uno o más agentes terapéuticos diferentes, así como también formas de dosificación unitarias de estas composiciones farmacéuticas, las cuales contienen una dosificación efectiva en el tratamiento o prevención de la adicción o reincidencia. Los métodos y composiciones de la invención son útiles en el tratamiento o prevención de la adicción a algún agente, que incluye alcohol, nicotina, mariguana, cocaína y anfetaminas, así como también comportamientos compulsivos y adictivos, que incluyen ludopatía y sobreactuación patológica.
MX2014002627A 2007-04-11 2008-04-11 Composiciones y metodos para profilaxis y tratamiento de adicciones. MX356965B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91120107P 2007-04-11 2007-04-11
PCT/US2008/060146 WO2008128126A1 (en) 2007-04-11 2008-04-11 Compositions and methods for prophylaxis and treatment of addictions

Publications (1)

Publication Number Publication Date
MX356965B true MX356965B (es) 2018-06-21

Family

ID=39864359

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009010854A MX2009010854A (es) 2007-04-11 2008-04-11 Composiciones y metodos para profilaxis y tratamiento de adicciones.
MX2014002627A MX356965B (es) 2007-04-11 2008-04-11 Composiciones y metodos para profilaxis y tratamiento de adicciones.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009010854A MX2009010854A (es) 2007-04-11 2008-04-11 Composiciones y metodos para profilaxis y tratamiento de adicciones.

Country Status (13)

Country Link
US (1) US8426439B2 (es)
EP (4) EP3788877B1 (es)
JP (2) JP5548120B2 (es)
KR (1) KR101622403B1 (es)
CN (3) CN110403942A (es)
AU (1) AU2008240158B2 (es)
BR (1) BRPI0810525B8 (es)
CA (1) CA2684059C (es)
ES (4) ES2830073T3 (es)
MX (2) MX2009010854A (es)
NZ (1) NZ580963A (es)
RU (1) RU2492858C2 (es)
WO (1) WO2008128126A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007292883B2 (en) 2006-09-08 2013-09-05 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8426439B2 (en) * 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2013202267B2 (en) * 2007-04-11 2015-03-19 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2299989B1 (en) * 2008-05-30 2019-01-02 Mylan Inc. Stabilized transdermal drug delivery system
US9226918B2 (en) 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
CN102348457A (zh) * 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
DK2846805T3 (en) * 2012-05-07 2019-03-18 Omeros Corp TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS
EP2846805B1 (en) * 2012-05-07 2018-11-21 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US20140072662A1 (en) * 2012-07-06 2014-03-13 Omeros Corporation Andrographis Paniculata Compositions and Methods for Treatment of Addictions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20150051191A1 (en) * 2013-08-15 2015-02-19 Medicinova, Inc. Treatment of alcoholism using ibudilast
WO2015153263A1 (en) * 2014-04-02 2015-10-08 Yale University Compositions and methods to treat addiction
WO2016065177A1 (en) * 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
KR101960262B1 (ko) * 2016-04-08 2019-03-21 공주대학교 산학협력단 전자 담배 조성물 내 담배 특이 니트로스아민류 및 카르보닐 화합물을 제거 및 생성의 억제, 전자 담배 조성물 흡연 시 발생하는 카르보닐 화합물 제거, 및 니코틴액의 갈변을 막기 위한 전자 담배 니코틴액용 첨가제 및 이를 포함하는 전자 담배 조성물
WO2018204689A1 (en) * 2017-05-04 2018-11-08 The Board Of Regents Of The University Of Texas System Methods of treating synthetic cannabinoid toxicity or overdose with rimonabant
KR102208012B1 (ko) * 2017-12-20 2021-01-27 가톨릭대학교 산학협력단 코카인 중독 특이적 바이오 마커
EP3834888A4 (en) * 2018-08-10 2022-05-11 Servicio Andaluz De Salud Agents for treatment of alcohol use disorder
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms
CN112569237B (zh) * 2019-09-30 2022-12-02 武汉大学 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途
US20230202978A1 (en) 2022-03-04 2023-06-29 Reset Pharmaceuticals, Inc. Co-crystal or salt

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3788207A (en) 1972-05-26 1974-01-29 Doherty Silentaire Top discharge roof ventilator
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
CN100376560C (zh) * 1997-10-27 2008-03-26 雷迪实验室有限公司 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
WO2000073791A1 (en) * 1999-05-27 2000-12-07 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
US6582738B2 (en) 1999-09-13 2003-06-24 Deseret Laboratories, Inc. Process for preparing chewing gum containing a nutritional supplement
EA200200424A1 (ru) * 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
AU7738100A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
US20020006942A1 (en) * 2000-02-24 2002-01-17 Davis Roger A. Methods of treating liver disorders and disorders associated with liver function
AU2001272098A1 (en) 2000-03-09 2001-09-17 Sanofi-Aventis Deutschland Gmbh Therapeutic uses of PPAR mediators
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
AU2001294192A1 (en) * 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
CN102140064A (zh) * 2001-06-12 2011-08-03 维尔斯达医疗公司 用于治疗代谢失调的化合物
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
EP1452521A4 (en) 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
US7524975B2 (en) * 2001-10-11 2009-04-28 Kaneka Corporation Peroxisome proliferator activated receptor ligand and process for producing the same
HUP0401647A3 (en) * 2001-10-16 2008-05-28 Reddys Lab Ltd Dr Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds
JP2005510563A (ja) 2001-11-26 2005-04-21 シェーリング　コーポレイション 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト
US20050096331A1 (en) * 2001-12-21 2005-05-05 Das Saibal K. Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7141561B2 (en) * 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
WO2004010992A1 (en) 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2006500378A (ja) 2002-08-21 2006-01-05 メルク　エンド　カムパニー　インコーポレーテッド 二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
JP2007504285A (ja) * 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
JP4931349B2 (ja) * 2003-01-23 2012-05-16 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
WO2004092417A2 (en) 2003-04-07 2004-10-28 Emory University Molecular correlates of cocaine addiction and methods for their use
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
EP1635832A2 (en) * 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2005007628A1 (en) * 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
CA2537660A1 (en) * 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2005037199A2 (en) * 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
JP2007509962A (ja) * 2003-10-31 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としての２１−複素環−４−アザステロイド誘導体
UA84035C2 (ru) 2003-10-31 2008-09-10 Янссен Фармацевтика Н.В. Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)
EP1743676A1 (en) * 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
PT1697371E (pt) * 2003-12-19 2007-08-03 Bristol Myers Squibb Co Heterocíclos azabicíclicos como moduladores do receptor de canabinóides
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
US7378418B2 (en) 2003-12-19 2008-05-27 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
KR20060131906A (ko) * 2004-02-20 2006-12-20 아스트라제네카 아베 Ｃｂ1 조절제로서 유용한 3-치환 1,5-디페닐피라졸 유도체
CA2560417C (en) 2004-04-03 2011-04-19 Astrazeneca Ab 1,2-diarylimidazole-4-carboxamide derivatives
KR20060134041A (ko) * 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 음식물 섭취 관리 방법
DE602005019555D1 (de) * 2004-05-06 2010-04-08 Galderma Res & Dev Biaromatische verbindungen, die rezeptoren des typs ppar(gamma) aktivieren, verfahren zu deren herstellung und deren verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
EP1778220A1 (en) * 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
DE102004038270A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006017861A2 (en) * 2004-08-13 2006-02-16 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
JP2006065511A (ja) * 2004-08-25 2006-03-09 Fujitsu Ltd 閲覧履歴提示システム
EP1841749A1 (en) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
AR050631A1 (es) 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
WO2006042245A1 (en) * 2004-10-11 2006-04-20 Dr. Reddy's Laboratories Ltd. Novel isoxazole compounds having ppar agonist activity
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US7411071B2 (en) * 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060270722A1 (en) 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009521448A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
CN101395164A (zh) * 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
US20070197606A1 (en) * 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
US20070232573A1 (en) * 2006-03-06 2007-10-04 Avestha Gengraine Technologies Pvt. Ltd. Ethanoic acid derivatives as dipeptidyl peptidase inhibitors
KR101333089B1 (ko) 2006-05-22 2013-11-27 재단법인 아산사회복지재단 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
JP5105297B2 (ja) * 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
CA2589393C (en) 2006-06-13 2016-04-12 Euroscreen S.A. Ligand for g-protein coupled receptor gpr72 and uses thereof
EP1867994B1 (en) 2006-06-13 2012-09-26 Euroscreen S.A. Ligand for G-protein coupled receptor GPR72 and uses thereof
JP2008044932A (ja) 2006-07-21 2008-02-28 Daiichi Sankyo Co Ltd チアゾリジンジオン化合物を含有する組成物
AU2007292883B2 (en) * 2006-09-08 2013-09-05 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US8426439B2 (en) * 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Also Published As

Publication number Publication date
US8426439B2 (en) 2013-04-23
JP2014139213A (ja) 2014-07-31
AU2008240158B2 (en) 2014-07-10
EP3053440B1 (en) 2020-08-12
ES2830073T3 (es) 2021-06-02
RU2492858C2 (ru) 2013-09-20
WO2008128126A8 (en) 2009-01-22
ES2586433T3 (es) 2016-10-14
JP5548120B2 (ja) 2014-07-16
CN105250285A (zh) 2016-01-20
BRPI0810525A2 (pt) 2014-10-07
ES2438768T3 (es) 2014-01-20
JP6010572B2 (ja) 2016-10-19
EP2141989A4 (en) 2010-07-14
CN101711107A (zh) 2010-05-19
CA2684059C (en) 2016-07-12
NZ580963A (en) 2012-08-31
RU2009141615A (ru) 2011-05-20
WO2008128126A1 (en) 2008-10-23
EP3788877B1 (en) 2024-08-07
ES2992321T3 (es) 2024-12-11
MX2009010854A (es) 2010-01-28
EP2141989A1 (en) 2010-01-13
CA2684059A1 (en) 2008-10-23
KR20090130125A (ko) 2009-12-17
KR101622403B1 (ko) 2016-05-31
BRPI0810525B8 (pt) 2021-05-25
BRPI0810525B1 (pt) 2021-05-11
EP3053440A1 (en) 2016-08-10
EP3788877A1 (en) 2021-03-10
CN110403942A (zh) 2019-11-05
JP2010523718A (ja) 2010-07-15
EP2612553B1 (en) 2016-06-08
US20090048232A1 (en) 2009-02-19
CN105250285B (zh) 2019-09-06
EP2612553A1 (en) 2013-07-10
AU2008240158A1 (en) 2008-10-23
EP2141989B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
MX356965B (es) Composiciones y metodos para profilaxis y tratamiento de adicciones.
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
MX361542B (es) Compuestos de morfinan.
MX2019006270A (es) Compuestos de morfinano.
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
SI1691892T1 (sl) Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
WO2008153632A3 (en) Compositions and methods for treating obesity and related disorders
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2007008756A (es) Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
TW200733976A (en) Method for the treatment of cognitive dysfunction
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
EP2101781A4 (en) METHOD FOR TREATING OR PREVENTING SYMPTOMS OF HORMONEY CHANGES
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе
WO2007104933A8 (en) Chemical compounds
TW200738232A (en) Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma